OBN Christmas Lecture
Tuesday 13 December 2022, Somerville College, Oxford
'New Hope for Chronic Neurodegenerative Disorders', Kindly Presented by Professor Dame Pamela Shaw
We are honoured to be welcoming Professor Dame Pamela Shaw as the OBN Christmas Lecturer this year, due to be delivered on 13 December at Somerville College in Oxford.
Professor Shaw is a Clinician Scientist in Neurology, an NIHR Senior Investigator and formerly a Wellcome Senior Clinical Fellow, who since 1991 has led a major multidisciplinary programme of research investigating genetic, molecular and neurochemical factors underlying neurodegenerative disorders of the human motor system.
During the lecture, Professor Shaw will provide an update on the major developments seen this year in the potential treatments and understanding of the most serious disorders of the brain and nervous system, including motor neurone disease as a neurodegenerative disorder poised for successful translation of new therapeutic developments.
Programme for the evening:
18.00 - 18.30 Guest Arrival
18.30 - 18.35 Welcome by Stuart Rose, CEO of OBN
18.35 – 19.35 Lecture and Audience Questions with Professor Dame Pamela Shaw
19.35 – 21.30 Christmas Drinks, Nibbles and Networking
More about Professor Dame Pamela Shaw
Professor Dame Pam Shaw is Professor of Neurology at the University of Sheffield and Director of: the Sheffield Institute for Translational Neuroscience (SITraN); the NIHR Sheffield Biomedical Research Centre for Translational Neuroscience; the Sheffield Care and Research Centre for Motor Neurone Disorders and the cross-faculty Sheffield Neuroscience Institute.
She is a Clinician Scientist in Neurology, formerly a Wellcome Trust Senior Fellow and an NIHR Senior Investigator. Her team investigates genetic, molecular and neurochemical mechanisms underlying ALS/MND; investigates new therapeutic targets and translates new neuroprotective and symptomatic treatment approaches into the clinic, including genetic therapy approaches.
She has authored more than 550 publications (H-index 112) and has been awarded >£120m in research income. Her research is funded by the MRC, Wellcome Trust, NIHR, MNDA, MyName'5 Doddie Foundation, EU and biotech/pharmaceutical industry partners.
From 2009-2016 she led the national UK Clinical Studies Group for ALS/MND, a clinical research and trials network which links 20 ALS/MND Care and Research Centres. Prof. Shaw has taken part in more than 25 ALS/MND clinical trials, including roles as Chief Investigator and Steering Committee member and also including several academic-led studies. She is an active member of the European Network for the Cure of ALS (ENCALS). She has active programmes in systematic biosample collection and biomarker identification in ALS/MND.
For the Event Terms and Conditions please click here.